Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 1

A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours

NCT ID: NCT05701527Sponsor: EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesLast updated: 2026-02-05

Summary

This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours

Detailed description

This study is a prospective, open label study which is divided into 4 parts. Part A will be dose escalation segment to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of EBC-129 monotherapy. Part B will be dose escalation segment to identify the MTD and RP2D of EBC-129 in combination with pembrolizumab. Part C (dose expansion cohort) will be performed in an expanded cohort of patients with advanced solid malignancies at the RP2D of EBC-129 as a monotherapy identified in the dose escalation segment, Part A. Part D (Dose Fractionation Cohort) will be performed in patients with advanced solid malignancies with cancer indications that have shown preliminary clinical activity in Part C.

Arms & interventions

  • DrugEBC-129

    EBC-129 will be administered on Day 1 of each 21-Day cycle (Parts A, B, and C), and two doses starting from Day 1 for 21-day cycle and three doses starting from Day 1 for 28-day cycle (Part D) via a 30-120-minute intravenous (IV) fusion.

  • DrugPembrolizumab

    Pembrolizumab will be administered at the dose of 200 mg IV every 21 days.

Outcome measures

Primary

  • Part A, Part B, Part C and Part D- Number of patients with serious adverse events (SAEs) and treatment emergent adverse events (TEAEs)

    Time frame: From pre-screening (≥28 days from planned date of treatment i.e. Day 1) until end of study (EOS i.e., 30 days from last dose). Approximately 2 years

  • Part A, Part B and Part D- Determination of Maximum tolerated dose (MTD)

    Time frame: Approximately 2 years

  • Part A, Part B and Part D- Determination of the Recommended Phase 2 dose (RP2D)

    Time frame: Approximately 2 years

  • Part C- Objective response rate (ORR)

    The number (%) of patients with a best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by investigator.

    Time frame: Day 1 through 12 cycles (each cycle is 21 days)

  • Part D- ORR

    The number (%) of patients with a best overall response of CR or PR per RECIST v1.1 as assessed by investigator.

    Time frame: Day 1 through 12 cycles (each cycle is 21 or 28 days)

Secondary

  • Part A and Part B- ORR

    Time frame: Day 1 through 12 cycles (each cycle is 21 days)

  • Part A, Part B, Part C and Part D- Disease control rate (DCR)

    Time frame: Approximately 3.3 years

  • Part A, Part B, Part C and Part D- Duration of Response (DoR)

    Time frame: Approximately 3.3 years

  • Part A, Part B, Part C and Part D- Time to Progression (TTP)

    Time frame: Approximately 3.3 years

  • Part A, Part B, Part C and Part D- Progression Free Survival (PFS)

    Time frame: Approximately 3.3 years

  • Part A, Part B, Part C and Part D- Overall Survival (OS)

    Time frame: Approximately 3.3 years

  • Part A, Part B, Part C and Part D- Maximum Plasma Concentration (Cmax) of EBC-129

    Time frame: Parts A, B and C: Cycle 1, 2, 3, and Cycle 4 (each cycle is 21 days); Part D: Cycle 1 (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Trough Concentration (Ctrough) of EBC-129

    Time frame: Parts A, B and C: Cycle 1, 2, 3, and Cycle 4 (each cycle is 21 days); Part D: Cycle 1 (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Area under the curve (AUC) of EBC-129

    Time frame: Parts A, B, and C: Cycle 1 and Cycle 2 (each cycle is 21 days); Part D: Cycle 1 (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Maximum plasma concentration at steady state (Cmax_ss) of EBC-129

    Time frame: Parts A, B, and C: Day 1 through 12 cycles (each cycle is 21 days); Part D: Day 1 through 12 cycles (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Trough concentration at steady state (Ctrough,ss) of EBC-129

    Time frame: Parts A, B, and C: Day 1 through 12 cycles (each cycle is 21 days); Part D: Day 1 through 12 cycles (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Area under the curve at steady state (AUC_ss) of EBC-129

    Time frame: Parts A, B, and C: Day 1 through 12 cycles (each cycle is 21 days); Part D: Day 1 through 12 cycles (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Accumulation ratios of EBC-129

    Time frame: Parts A, B, and C: Day 1 through 12 cycles (each cycle is 21 days); Part D: Day 1 through 12 cycles (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Time to maximum plasma concentration (Tmax) of EBC-129

    Time frame: Parts A, B, and C: Day 1 through 12 cycles (each cycle is 21 days); Part D: Day 1 through 12 cycles (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Half-life (t1/2) of EBC-129

    Time frame: Parts A, B, and C: Day 1 through 12 cycles (each cycle is 21 days); Part D: Day 1 through 12 cycles (each cycle is 21 or 28 days)

  • Part B- Cmax of Pemrolizumab

    Time frame: Day 1 through 12 cycles (each cycle is 21 days)

  • Part B- Ctrough of Pemrolizumab

    Time frame: Day 1 through 12 cycles (each cycle is 21 days)

  • Part B- AUC of Pemrolizumab

    Time frame: Cycle 1 and 2 (each cycle is 21 days)

  • Part B- Tmax of Pemrolizumab

    Time frame: Day 1 through 12 cycles (each cycle is 21 days)

  • Part B- t1/2 of Pemrolizumab

    Time frame: Day 1 through 12 cycles (each cycle is 21 days)

  • Part A, Part B, Part C and Part D- Number of patients with detectable Anti-drug antibodies (ADAs)

    Time frame: Parts A, B, and C: Day 1 through 12 cycles (each cycle is 21 days); Part D: Day 1 through 12 cycles (each cycle is 21 or 28 days)

  • Part A, Part B, Part C and Part D- Number of patients with neutralising antibodies

    Time frame: Parts A, B, and C: Day 1 through 12 cycles (each cycle is 21 days); Part D: Day 1 through 12 cycles (each cycle is 21 or 28 days)

  • Part A- Comparison of tumour responses

    Time frame: Approximately 1.8 years

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: 1. Male or female patients ≥18 years (US) or ≥21 years (Singapore) old 2. Body weight within ≥40 kg - ≤100 kg during Parts A and B, and ≤120 kg during all other parts of the study 3. Demonstrated progression of a locally advanced unresectable or metastatic solid tumour with no alternative standard-of-care therapeutic option with a proven clinical benefit, or are intolerant to these therapies 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 for Part A and 0-1 for Parts B, C and D 5. Hepatic function and adequate renal function, as per protocol standard 6. Adequate bone marrow function as per protocol standard Exclusion Criteria: 1. Unable or not willing to provide tumour tissue sample (from archival tissue or de-novo biopsy) unless if there is a significant risk for the patient to undergo biopsy 2. Has received investigational or anti-cancer therapy within 4 weeks (28 days) prior to starting study drug 3. Is receiving any concomitant anti-cancer therapy 4. Known severe hypersensitivity to E coli-derived products or filgrastim or peg-filgrastim and have significant allergies to such biological products 5. Has clinically active brain metastases 6. Has received prior radiation therapy 7. Has received prophylactic administration of haematopoietic colony stimulating factors within 4 weeks (28 days) prior to starting study drug 8. Patients concurrently using any strong P-glycoprotein (P-gp) inducers/inhibitors or strong cytochrome P3A (CYP3A) inhibitors within 14 days prior to the first dose of study drug or patients that use restricted or prohibited medications listed in the concomitant and other treatments section of the protocol 9. Pregnancy or breast feeding 10. For patients receiving pembrolizumab: 1. Has an active autoimmune disease that has required systemic treatment in the past 2 years 2. Patients who, according to the currently approved Keytruda (pembrolizumab) US package insert (USPI)/summary of product characteristics, had an immune-related adverse event (irAE) for which permanent discontinuation is mandated (any Grade 4 event and Grade 3 events of pneumonitis, hepatitis, and nephritis). Also, patients without formal contraindication due to previous irAE with any immune checkpoint inhibitor (approved or investigational) are not eligible if the AE has not resolved to grade 1 or better and/or still requires steroids (\>10 mg of prednisone equivalent per day) for ongoing management. 3. Patients with a history of pneumonitis/interstitial lung disease, patients who received live vaccines within 30 days of enrolment, and patients who discontinued prior immune checkpoint inhibitors due to Grade 2 myocarditis are excluded from enrolment into pembrolizumab-containing cohorts 11. Has had a major surgical procedure within 4 weeks (28 days) from starting the study drug 12. Patients with active or chronic corneal disorders, with other active ocular conditions requiring ongoing therapy or with any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy 13. Active infection including HIV, Hepatitis B or Hepatitis C

Study locations (2)

University of Colorado Hospital (UCH) - University of Colorado Cancer Center (UCCC) - Neuroendocrine Tumor Center

Aurora, Colorado, 80045-2517

Recruiting
Sunnie Kim · Principal Investigator

UT MD Anderson Cancer Center

Houston, Texas, 77030

Recruiting
Meric-Bernstam Funda · Principal Investigator